Polypharmacy Other
Conditions
Interventions
According to the Pharmaceutical Care Network Europe (PCNE) definition, medication reviews are structured patient interviews with systematic evaluations of their medication history with the aim of opti
Sponsors
Medical University of Vienna
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with intake of =8 systemically available drugs (in case of combination products, =8 active ingredients, also including over-the-counter drugs, especially if they are on the list of interaction relevant over the counter drugs) 2. Patients >18 years of age 3. Patients signing informed consent
Exclusion criteria
Exclusion criteria: 1. Patients not willing to adhere to the study’s requirements 2. Patients unable to understand the nature and purpose of the study 3. Previous participation in a structured medication review type 2a
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug-related problems assessed using a structured medication review type 2a (questionnaire) at baseline, after 3 to 4 months, and after 6 to 9 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Therapy adherence assessed using a structured medication review type 2a (questionnaire) at baseline, after 3 to 4 months, and after 6 to 9 months 2. Health literacy was assessed using a structured medication review type 2a (questionnaire) at baseline, after 3 to 4 months, and after 6 to 9 months 3. The effects of one structured medication review type 2a at months 3 to 4 compared to two structured medication reviews type 2a at baseline and month 3 to 4 on drug-related problems (questionnaire) 4. The number of drug-related problems assessed using a structured medication review type 2a (questionnaire) at baseline, after 3 to 4 months, and after 6 to 9 months 5. The number of medications and active ingredients assessed using a structured medication review type 2a (questionnaire) at baseline, after 3 to 4 months, and after 6 to 9 months 6. Relative and absolute frequency of contraindications or severe drug-related problems that require intervention by clinical pharmacologists/clinical pharmacists or treating physicians, assessed using a structured medication review type 2a (questionnaire) at baseline, after 3 to 4 months, and after 6 to 9 months 7. Associations of gender, age, and number of medications/active ingredients at baseline with the number of drug-related problems assessed using a structured medication review type 2a at baseline Added 26/03/2025: 1. Descriptive statistics of patients participating in part 2 of the study per group and presentations of reasons why the study was terminated before part 1 2. Absolute and relative number of contributors to drug-related problems (e.g., double prescriptions, dosing errors, etc) and the impact of a structured medication review type 2a (questionnaire) on these parameters at baseline, after 3 to 4 months, and after 6 to 9 months 3. Change in drug-related problems (or contributors) within each group from baseline to month 3 to 4 or month 6 to 9 using a structured medication review type 2a (questionnaire) will be analyse | — |
Countries
Austria
Contacts
Public ContactStefan Deibl
Outcome results
None listed